Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ICLR
ICLR logo

ICLR Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy ICON PLC (ICLR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
101.100
1 Day change
-0.18%
52 Week Range
211.000
Analysis Updated At
2026/03/20
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

ICON PLC (ICLR) is not a strong buy for a beginner, long-term investor at this time. The stock is facing significant uncertainties due to internal accounting investigations, weak financial performance, and mixed analyst sentiment. While the current price may reflect some of these risks, the lack of positive trading signals and ongoing challenges suggest holding off on investment until more clarity emerges.

Technical Analysis

The technical indicators show a bearish trend. The MACD is positive but contracting, RSI is neutral at 36.178, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support is at 97.063, with resistance at 102.663. The stock is trading near support levels but lacks a clear upward momentum.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
8
Buy
3

Positive Catalysts

  • Some analysts believe the selloff related to the accounting investigation is overdone, and the current valuation may present a compelling risk/reward ratio. Jefferies and TD Cowen upgraded the stock to Buy, citing potential upside.

Neutral/Negative Catalysts

  • The company is undergoing an internal accounting investigation, which has led to overstated revenues in 2023-2024 and withdrawal of FY25 guidance. Analysts have significantly lowered price targets, and financial performance has been weak with a sharp drop in net income (-98.81% YoY) and EPS (-98.73% YoY).

Financial Performance

In Q3 2025, revenue increased marginally by 0.63% YoY to $2.04 billion. However, net income and EPS dropped sharply by -98.81% and -98.73% YoY, respectively. Gross margin also declined to 22.32%, down -9.08% YoY, indicating significant profitability challenges.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are mixed but leaning negative. Recent downgrades from Rothschild & Co Redburn, BofA, and Nephron Research highlight concerns about accounting issues and overstated revenues. However, Jefferies and TD Cowen upgraded the stock to Buy, citing the selloff as overdone and the current valuation as attractive. Price targets have been significantly reduced across the board, ranging from $75 to $135.

Wall Street analysts forecast ICLR stock price to rise
13 Analyst Rating
Wall Street analysts forecast ICLR stock price to rise
6 Buy
7 Hold
0 Sell
Moderate Buy
Current: 101.280
sliders
Low
172
Averages
202.67
High
222
Current: 101.280
sliders
Low
172
Averages
202.67
High
222
Citi
Patrick Donnelly
Neutral
downgrade
$200 -> $120
AI Analysis
2026-03-11
Reason
Citi
Patrick Donnelly
Price Target
$200 -> $120
AI Analysis
2026-03-11
downgrade
Neutral
Reason
Citi analyst Patrick Donnelly lowered the firm's price target on Icon to $120 from $200 and keeps a Neutral rating on the shares. The firm updated models in the life science tools and diagnostics group post the Q4 reports. Citi sees room for upside to the Q1 outlooks if biopharma activity continues to improve. The firm named Agilent its top tools pick, Natera its top diagnostics pick, and Charles River its top contract research organization pick.
Barclays
Luke Sergott
Equal Weight
downgrade
$200 -> $120
2026-03-06
Reason
Barclays
Luke Sergott
Price Target
$200 -> $120
2026-03-06
downgrade
Equal Weight
Reason
Barclays analyst Luke Sergott lowered the firm's price target on Icon to $120 from $200 and keeps an Equal Weight rating on the shares. The firm cites uncertainty around the company's accounting issues and possibility that management restates backlog for the target cut.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ICLR
Unlock Now

People Also Watch